Skip to content
  • About the Firm
  • Our People
  • Our Expertise
    • Alter Ego and Entity Relationships
    • Construction Disputes
    • Economic Damages
    • Business Valuation
    • Foreign Corrupt Practices Act
    • Forensic Accounting – Compliance with GAAP and GAAS
    • Forensic Accounting – Investigations of Improprieties
    • Intellectual Property Damages
    • Intellectual Property Valuation and Licensing
    • Labor Disputes
    • Large-Scale Data
    • Management Advisory Services
    • Mergers & Acquisitions Advisory Services
    • Royalty and License Compliance Examinations
    • White Collar Crime Investigations
  • Offices
    • San Francisco – Bay Area
      • Burlingame
      • Campbell
      • Concord
      • San Francisco
      • Santa Rosa
    • Chico
    • Fresno
    • Idaho Falls
    • Las Vegas
    • Los Angeles
  • Insights & News
  • Opportunities
Menu
  • About the Firm
  • Our People
  • Our Expertise
    • Alter Ego and Entity Relationships
    • Construction Disputes
    • Economic Damages
    • Business Valuation
    • Foreign Corrupt Practices Act
    • Forensic Accounting – Compliance with GAAP and GAAS
    • Forensic Accounting – Investigations of Improprieties
    • Intellectual Property Damages
    • Intellectual Property Valuation and Licensing
    • Labor Disputes
    • Large-Scale Data
    • Management Advisory Services
    • Mergers & Acquisitions Advisory Services
    • Royalty and License Compliance Examinations
    • White Collar Crime Investigations
  • Offices
    • San Francisco – Bay Area
      • Burlingame
      • Campbell
      • Concord
      • San Francisco
      • Santa Rosa
    • Chico
    • Fresno
    • Idaho Falls
    • Las Vegas
    • Los Angeles
  • Insights & News
  • Opportunities
Home  /  Insight & News  /  Hemming Morse Partner Carl Saba was retained as an expert by the US Department of Justice to estimate the loss to Theranos investors in its Series C-1 and C-2 rounds.

Hemming Morse Partner Carl Saba was retained as an expert by the US Department of Justice to estimate the loss to Theranos investors in its Series C-1 and C-2 rounds.

  • May, 2023

Below is a link to the Court’s decision, which cites the Saba Expert Report as “having provided a reasonable protocol in arriving at a loss amount that contains several indicia of reliability”.

Court’s Decision

Back to all articles
Hm-rebrandlogos-Finals-2019
Firm Information
  • About the Firm
  • Our People
  • Our Expertise
  • Insights & News
  • Opportunities
Office Locations
  • San Francisco
  • Los Angeles
  • Concord
  • Campbell
  • Las Vegas
  • Santa Rosa
  • Fresno
  • Chico
  • Burlingame
  • Idaho Falls
Have Questions?
Inquire about a potential matter
Inquire about joining our team
  • Copyright © 2008-2019 Hemming Morse. All rights reserved.
  • Branding and Web by Red Mallard